| Summary: | Objective: To evaluate the clinical efficacy of dendritic cell-activated cytokine-induced killer (DC-CIK) cells combined with conventional therapy in the treatment of malignant tumors.Methods: A total of 100 patients with malignant tumors were randomly divided into two groups. Treatment group received conventional therapy combined with DC-CIK while control group received conventional therapy alone. The short-term efficacy, adverse reactions and changes of lymphocyte subpopulation were all compared between two groups after treatment.Results: The overall response rate (ORR) was higher in treatment group (86.00%) than in control group (54.00%), the difference was statistically significant (P<0.05). White blood cell count (WBC) reduced after treatment when compared with treatment before (P=0.001), but liver and kidney function had no obvious change in treatment group (P>0.05). WBC reduced markedly, but the level of alanine aminotransferase (ALT) increased obviously after treatment in control group (P<0.001). WBC was higher, but the level of ALT was lower in treatment group than in control group (P<0.001). However, there was no difference between two groups regarding serum creatinine (Scr) and blood urea nitrogen (BUN) (P>0.05). In treatment group, the levels of CD3+, CD3+CD4+, CD3+CD8+, and CD3+CD56+ increased (P<0.05), but the level of CD4+/CD8+ had no significant change (P>0.05). In control group, the levels of CD3+ and CD3+CD4+ reduced (P<0.05), while the levels of CD3+CD8+, CD3+CD56+ and CD4+/CD8+ had no significant change (P>0.05). The levels of CD3+, CD3+CD4+, CD3+CD8+ and CD3+CD56+ in treatment group were higher than those in control group (P<0.01), whereas CD4+/CD8+ was lower than that in control group (P<0.01).Conclusion: DC-CIK combined with conventional therapy, safe and effective, is capable of promoting the recovery of leukocytes and liver and kidney function, and improving the cellular immune function, which may provide a new therapeutic regimen for patients with malignant tumors.
|
|---|
